Cite
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.
MLA
Lipton, Richard B., et al. “Effects of Fremanezumab in Patients with Chronic Migraine and Comorbid Depression: Subgroup Analysis of the Randomized HALO CM Study.” Headache: The Journal of Head & Face Pain, vol. 61, no. 4, Apr. 2021, pp. 662–72. EBSCOhost, https://doi.org/10.1111/head.14097.
APA
Lipton, R. B., Cohen, J. M., Galic, M., Seminerio, M. J., Yeung, P. P., Aycardi, E., Bigal, M. E., Bibeau, K., & Buse, D. C. (2021). Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. Headache: The Journal of Head & Face Pain, 61(4), 662–672. https://doi.org/10.1111/head.14097
Chicago
Lipton, Richard B., Joshua M. Cohen, Maja Galic, Michael J. Seminerio, Paul P. Yeung, Ernesto Aycardi, Marcelo E. Bigal, Kristen Bibeau, and Dawn C. Buse. 2021. “Effects of Fremanezumab in Patients with Chronic Migraine and Comorbid Depression: Subgroup Analysis of the Randomized HALO CM Study.” Headache: The Journal of Head & Face Pain 61 (4): 662–72. doi:10.1111/head.14097.